CEO Fabian Gerlinghaus shares a business overview and VP of R&D Daniele Malleo gives a hands on tour of how the Cell Shuttle works.

Paul Matteis comments on Biogen and Vertex earnings, discusses recent news on BioMarin and Sage.

Amanda Burkhardt describes how phages selectively target bacteria of interest and how PHIOGEN's platform is designed for broad spectrum.

Angela Holmes explains how her company uses computational power to help companies with drug development.

Raphaël Ognar discusses the results we have seen in the NK space over recent years.

Imran Alibhai describes how Tvardi is taking the approach of using a non-covalent inhibitor to prevent the activation of STAT3.

CPRIT Deputy Executive Officer and General Counsel Kristen Doyle explains the details of this Texas cancer research funding program.

Jochen Reiser talks about the reach of UTMB and the science happening in Galveston, and highlights immunology approaches to kidney disease.

Omid Veiseh explains the idea behind Rice's Biotech Launchpad, describes the cytokine company Avenge Bio, and talks about other technologies

Bill McKeon describes TMC's news campus that is focused on translational research.

Ann Tanabe gives a preview of the 12th annual Texas Life Science Forum from Houston.

Andrew Ward describes the foundational research Scripps has made regarding coronavirus and HIV research.

Travis Young explains the idea behind Calibr and describes a switchable CAR-T program that has been developed there.

Rishi Bedi explains how AI might be impacting protein design, genetic medicine, immuno-oncology and more in the future.

Dr. Chen talks about emerging technologies he is excited about such logic gating, AI, and multi-specific nanobots.

Paul Rennert gives an update on Aleta, and summarizes data at #SITC23 from the IO 2.0, cytokine, TGF beta, Treg, lymphoid, and CAR-T spaces.

Zen Su gives an overview Marengo, his view of #SITC23, and SITC's new biotech initiative.

John Connolly describes trends he is seeing in cell therapy, bi-specific engagers, myeloid checkpoint targets, and combinations.

Steven Kelly describes how Carisma is leveraging Moderna's mRNA and LNP expertise to engineer monocytes in-vivo to act as a cell therapy.

Dr. Hege discusses the latest in cell therapy, new modalities, and a biotech initiative that SITC is launching.